Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme.
about
Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement.Outpatient parenteral antimicrobial therapy and antimicrobial stewardship: challenges and checklistsPopulation pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis.Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin.Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK teaching hospital-based service.Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis.Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical featuresEconomic evaluation of treatment for MRSA complicated skin and soft tissue infections in Glasgow hospitals.Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service.Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults.
P2860
Q27687541-1E80DAC2-E54F-45AB-8CDD-E680208C62ABQ28088622-3B2A1722-9C84-42EC-ACBC-3BC50156AEBFQ36243693-0CFE978C-3B14-4DB5-A8F7-28B9C4EC46B1Q36929387-10B1E0F7-4A0B-4C9F-8ABC-B95395D1A635Q37900838-426B250D-C7B3-4814-BABD-13389C0B21B4Q39200930-919D12DD-A7F2-4699-BF72-EC7A0642FD7AQ40695076-74C3AEDB-E941-4D22-962D-6078208FAECBQ42089497-90DEA37F-5904-4190-8134-42650B26D918Q42249120-84E7E994-65E5-4017-93DA-4DBC3FE34CA3Q42947797-CB6B9980-5033-4F03-9AE0-09E0EDD9B766Q48197188-B1FA565B-41F7-432C-AAD6-383A8FA8FB5A
P2860
Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Development of teicoplanin dos ...... otic therapy (OPAT) programme.
@en
Development of teicoplanin dos ...... parenteral antibiotic therapy
@nl
type
label
Development of teicoplanin dos ...... otic therapy (OPAT) programme.
@en
Development of teicoplanin dos ...... parenteral antibiotic therapy
@nl
prefLabel
Development of teicoplanin dos ...... otic therapy (OPAT) programme.
@en
Development of teicoplanin dos ...... parenteral antibiotic therapy
@nl
P2093
P2860
P356
P1476
Development of teicoplanin dos ...... otic therapy (OPAT) programme.
@en
P2093
Alison H Thomson
Elspeth Lamont
Lindsay Semple
Merran Macpherson
R Andrew Seaton
P2860
P304
P356
10.1093/JAC/DKP147
P407
P577
2009-05-02T00:00:00Z